| Literature DB >> 27402381 |
Sun Young Cho1, Ji-Man Kang2, Young Eun Ha1, Ga Eun Park1, Ji Yeon Lee1, Jae-Hoon Ko1, Ji Yong Lee1, Jong Min Kim2, Cheol-In Kang1, Ik Joon Jo3, Jae Geum Ryu4, Jong Rim Choi4, Seonwoo Kim5, Hee Jae Huh6, Chang-Seok Ki6, Eun-Suk Kang6, Kyong Ran Peck1, Hun-Jong Dhong7, Jae-Hoon Song1, Doo Ryeon Chung8, Yae-Jean Kim9.
Abstract
BACKGROUND: In 2015, a large outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection occurred following a single patient exposure in an emergency room at the Samsung Medical Center, a tertiary-care hospital in Seoul, South Korea. We aimed to investigate the epidemiology of MERS-CoV outbreak in our hospital.Entities:
Mesh:
Year: 2016 PMID: 27402381 PMCID: PMC7159268 DOI: 10.1016/S0140-6736(16)30623-7
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321
Figure 1(A) Floor plan of the emergency room and schematic views of (B) zone II, (C) zone III, and (D) zone IV
Patient 14 was cared for in zones II–IV between May 27 and May 29, 2015.
Demographic and epidemiological data of all contacts and confirmed cases of MERS-CoV infection
| Patients (n=675) | Visitors (estimated n=683) | Health-care workers (n=218) | Patients (n=33) | Visitors (n=41) | Patients and visitors (n=74) | Health-care workers (n=8) | ||
|---|---|---|---|---|---|---|---|---|
| Age (years) | 49 (0–95, 25–63) | NA | 30 (22–61, 26–34) | 62 (16–84, 48–68) | 55 (31–75, 46–59) | 57 (16–84, 46–65) | 38 (24–55, 33–39) | |
| Male | 320 (47%) | NA | 85 (39%) | 17 (52%) | 31 (76%) | 48 (65%) | 5 (63%) | |
| Underlying disease | ||||||||
| Any underlying disease | 311 (46%) | .. | .. | 24 (73%) | .. | .. | .. | |
| Malignancy or immunosuppression | 195 (29%) | .. | .. | 12 (36%) | .. | .. | .. | |
| Endocrine disease | 78 (12%) | .. | .. | 8 (24%) | .. | .. | .. | |
| Cardiovascular disease | 50 (7%) | .. | .. | 6 (18%) | .. | .. | .. | |
| Neurological disease | 40 (6%) | .. | .. | 1 (3%) | .. | .. | .. | |
| Liver disease | 29 (4%) | .. | .. | 1 (3%) | .. | .. | .. | |
| Respiratory disease | 28 (4%) | .. | .. | 3 (9%) | .. | .. | .. | |
| Renal disease | 21 (3%) | .. | .. | 1 (3%) | .. | .. | .. | |
| Group A | 117 (17%) | 122 | .. | 23/30 (77%) | 24/38 (63%) | 47/68 (69%) | .. | |
| Zone II | 57 (8%) | 58 (8%) | .. | 13/30 (43%) | 12/38 (32%) | 25/68 (37%) | .. | |
| Zone III | 22 (3%) | 26 (4%) | .. | 7/30 (23%) | 9/38 (24%) | 16/68 (24%) | .. | |
| Zone IV | 38 (6%) | 38 (6%) | .. | 3/30 (10%) | 3/38 (8%) | 6/68 (9%) | .. | |
| Group B | 58 (9%) | 58 (8%) | .. | 3/30 (10%) | 3/38 (8%) | 6/68 (9%) | .. | |
| Group C | 500 (74%) | 503 | .. | 4/30 (13%) | 11/38 (29%) | 15/68 (22%) | .. | |
| May 27 to May 27 | 160 (24%) | 162 (24%) | 46 (21%) | 8/30 (26%) | 12/38 (32%) | 20/68 (29%) | 0 | |
| May 28 to May 28 | 162 (24%) | 162 (24%) | 0 (0) | 1/30 (3%) | 1/38 (3%) | 2/68 (3%) | 0 | |
| May 29 to May 29 | 190 (28%) | 190 (28%) | 97 (44%) | 0 | 0 | 0 | 0 | |
| May 27 to May 28 | 77 (11%) | 83 (12%) | 21 (10%) | 14/30 (46%) | 20/38 (53%) | 34/68 (50%) | 0 | |
| May 27 to May 29 | 31 (5%) | 31 (5%) | 51 (23%) | 7/30 (23%) | 4/38 (11%) | 11/68 (16%) | 5/5 (100%) | |
| May 28 to May 29 | 55 (8%) | 55 (8%) | 3 (1%) | 0 | 1/38 (3%) | 1/68 (1%) | 0 | |
| Medical doctor | .. | .. | 91 (42%) | .. | .. | .. | 2/5 (40%) | |
| Nurse | .. | .. | 79 (36%) | .. | .. | .. | 3/5 (60%) | |
| Nursing assistant or radiology technician | .. | .. | 31 (14%) | .. | .. | .. | 0 | |
| Others | .. | .. | 17 (8%) | .. | .. | .. | 0 | |
Data are median (range, IQR), n (%), or n/N (%). MERS-CoV=Middle East respiratory syndrome coronavirus. NA=not available.
Three patients and three visitors with confirmed infection were not included in the initial contact investigation (appendix p 5).
Three health-care workers (one security guard, one physician, and one patient transfer agent) with confirmed infection were not initially identified as contacts.
Five extra visitors were added to group A and three extra visitors were added to group C because there were two or more visitors with confirmed MERS-CoV infection per patient.
Figure 2(A) Confirmed cases of MERS-CoV infection by date of symptom onset after exposure to Patient 14 and (B) incubation periods
(A) 73 confirmed cases are shown here; six patients were excluded because we could not determine the date of symptom onset, and data were not available from three visitors. (B) Incubation periods were calculated from data of 59 patients and visitors in groups A–C. MERS-CoV=Middle East respiratory syndrome coronavirus.
Figure 3Attack rates (A) by groups of patient contacts and (B) by date of exposure
Error bars represent 95% CI. MERS-CoV=Middle East respiratory syndrome coronavirus.
Risk factors for transmission of MERS-CoV in all patient contacts and in patients in group A
| Age (>60 years) | 1·43 (0·62–3·28) | 0·71 | |
| Male | 0·77 (0·35–1·71) | 0·48 | |
| Any underlying disease | 1·97 (0·79–5·41) | 0·12 | |
| Group | <0·0001 | ||
| A | 4·32 (1·22–24·49) | 0·016 | |
| A | 25·59 (8·22–111·39) | <0·0001 | |
| Stay in the same zone as Patient 14 for >2 h | 1·74 (0·48–8·37) | 0·42 | |
| Location of exposure to Patient 14 | 0·010 | ||
| Zone II | 0·91 (0·23–3·83) | 1·00 | |
| Zone II | 5·62 (1·25–36·84) | 0·019 | |
MERS-CoV=Middle East respiratory syndrome coronavirus.
Bonferroni's correction.
Figure 4Location of Patient 14 during his stay in the emergency room
HEPA=high-efficiency particulate arrestance.